



11-09-05

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Daniel P. Gold
		Art Unit	1644
		Examiner Name	Schwadron, Ronald B.
Total Number of Pages in This Submission	22 + references	Attorney Docket Number	30795-702.201

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> <u>Power of Attorney</u> , Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Forms 08A and B
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s)	References
<input type="checkbox"/> Certified Copy of Priority Document(s)	postcard	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


Firm or Individual name	Russell T. Boggs, Reg.No. 55,011		
Signature			
Date	November 7, 2005		

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence and all marked attachments are being deposited by Express Mail, Express Mailing Label No.: EV 517730991US on -Oct-05 addressed to: Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
Typed or printed name	Ann Lygas		
Signature		Date	November 8, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Docket No. 30795-702.201  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Daniel P. Gold	)	Group Art Unit: 1644
Serial Number: 09/927,122	)	Examiner: Schwadron, Ronald B.
Filing Date: August 10, 2001	)	<b>CONFIRMATION NO: 4261</b>
Title: Method and Composition for Altering a T Cell	)	
Mediated Pathology	)	

FILED BY EXPRESS MAIL ON: November 8, 2005

EXPRESS MAIL LABEL NO.: EV517730991US

Mail Stop IDS  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97**

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached forms PTO/SB/08A and PTO/SB/08B. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached forms PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

11/10/2005 CNGUYEN 00000034 232415 09927122

01 FC:1806 180.00 DA

☐ 37 CFR §1.97(b). This Information Disclosure Statement should be considered by the Office because:

- ☐ (1) It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d);  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application;  
-- OR --
- ☐ (3) It is being filed before the mailing date of the first Office Action on the merits;  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.

☒ 37 CFR §1.97(c). Although this Information Disclosure Statement is being filed after the period specified in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final office action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise closes prosecution on the merits, this Information Disclosure Statement should be considered because it is accompanied by one of:

- ☐ a certification as specified in §1.97(e) provided concurrently herewith;  
-- OR --
- ☒ a fee of \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 CFR §1.97(d). Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, it is being filed before payment of the issue fee and should be considered because it is accompanied by:

- A. a certification as specified in §1.97(e); and
- B. a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.

☐ 37 CFR §1.97(e). A certification signed by an Attorney of Record is provided herewith as required under 37 CFR §§1.97(b) and (c).

☒ 37 CFR §1.98(a)(2). The content of the Information Disclosure Statement is as follows:

- ☐ Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed herewith.  
-- OR --
- ☒ Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed.  
-- AND/OR --
- ☒ Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2).  
-- AND/OR --
- ☐ Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).

- ☒ 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or references.
- ☐ Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
- ☒ Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation of the non-English language references is provided herewith
- ☐ Attached are copies of search report(s) from corresponding patent application(s), submitted in accordance with MPEP 609 D in support of the attached certification under 37 CFR §1.97(e)(1).
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 30795-702.201).


Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: \_\_\_\_\_

11/7/05

By: \_\_\_\_\_

  
Russell T. Boggs, Ph.D.  
Reg. No. 55,011

650 Page Mill Road  
Palo Alto, CA 94304-1050  
(650) 493-9300  
Customer No. 021971

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	09/927,122	
				Filing Date	August 10, 2001	
				First Named Inventor	Daniel P. Gold	
				Art Unit	1644	
				Examiner Name	Schwadron, Ronald B.	
Sheet	3	of	18	Attorney Docket Number	30795-702.201	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	48	US-5162111	11-10-1992	Grabstein et al.		
	49	US-4338397	07-06-1982	Gilbert et al.		
	50	US-4399216	08-16-1983	Axel et al.		
	51	US-4444878	04-24-1984	Henry P. Paulus		
	52	US-4468464	08-28-1984	Cohen et al.		
	53	US-4512922	04-23-1985	Jones et al.		
	54	US-4634665	01-06-1987	Axel et al.		
	55	US-4704362	11-03-1987	Itakura et al.		
	56	US-4816249	03-28-1989	Levy et al.		
	57	US-4840896	06-20-1989	Reddy et al.		
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	58	JP-62089621 Abstract	01-07-1992	Immunex Corp.		
	59	JP-64-027492 Abstract	01-30-1989	Amgen		
	60	JP-01-193227 Abstract	08-03-1989	Res Dev Corp of JP		
	61	JP-62230729 Abstract	10-09-1987	Sumitomo Pharm. Co.		
	62	WO98/16246	04-23-1998	Johns Hopkins U.		
	63	WO97/13502	04-17-1997	Immunex Corp.		
	64	WO96/10395	04-11-1996	CSL Ltd.		
	65	WO96/07740 w/Abstract	03-14-1996	Institut Pasteur		
	66	WO94/01133	01-20-1994	Schering Corp.		
	67	WO93/20835	10-28-1993	Schering Corp.		
	68	WO91/05046	04-18-1991	Immunex Corp.		
	69	WO88/00832	02-11-1988	Immunex Corp.		
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	09/927,122	
				Filing Date	August 10, 2001	
				First Named Inventor	Daniel P. Gold	
				Art Unit	1644	
				Examiner Name	Schwadron, Ronald B.	
Sheet	2	of	18	Attorney Docket Number	30795-702.201	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	24	US-5891429	04-06-1999	Clark et al.		
	25	US-5891432	04-06-1999	William Soo Hoo		
	26	US-5895646	04-20-1999	Elizabeth A. Wang		
	27	US-5900238	05-04-1999	Gombotz et al.		
	28	US-5904920	05-18-1999	Dranoff et al.		
	29	US-5929196	07-27-1999	Kissel et al.		
	30	US-5942253	08-24-1999	Gombotz et al.		
	31	US-5980911	11-09-1999	Corner et al.		
	32	US-5728377	03-17-1998	Sarris et al.		
	33	US-5602007	02-11-1997	Dunn et al.		
	34	US-5679356	10-21-1997	Bonnem et al.		
	35	US-5679347	10-21-1997	Porcelli et al.		
	36	US-5580561	12-03-1996	Cercek et al.		
	37	US-5478556	12-26-1995	Elliott et al.		
	38	US-5334379	08-02-1994	Pillai et al.		
	39	US-5179017	01-12-1993	Axel et al.		
	40	US-5229496	07-20-1993	Deeley et al.		
	41	US-5254534	10-19-1993	Tachibana et al.		
	42	US-5078996	01-07-1992	Conlon III et al.		
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	43	FR-2658432	08-23-1991	Medgenix Group SA		
	44	JP-2000256209 Abstract	09-19-2000	Morinaga Milk Ind. Co. Ltd.		
	45	JP-10295379 Abstract	11-10-1998	GSF Forsch.Unwelt		
	46	JP-02-002390 Abstract	01-08-1990	Sumitomo Chem.Co.		
	47	JP-02-076820 Abstract	03-16-1990	Ajinomoto Co. Inc.		
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	1	of	18	Attorney Docket Number	30795-702.201

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-6361948 B1	03-26-2002	Tricoli et al.	
	2	US-6348449 B1	02-19-2002	Weiner et al.	
	3	US-6342216 B1	01-29-2002	Fidler et al.	
	4	US-6338962	01-15-2002	Frederick M. Boyce	
	5	US-6338953 B1	01-15-2002	Boyce et al.	
	6	US-6331415 B1	12-18-2001	Cabilly et al.	
	7	US-6312718 B1	11-06-2001	Popescu et al.	
	8	US-6312690	11-06-2001	Edelman et al.	
	9	US-6309632 B1	10-20-2001	Jan M. Agosti	
	10	US-6274175 B1	08-14-2001	Gombatz et al.	
	11	US-6120807	09-19-2000	Gombatz et al.	
	12	US-6096313	08-01-2000	Jager et al.	
	13	US-6087110	07-11-2000	Wang et al.	
	14	US-6083703	07-04-2000	Wang et al.	
	15	US-6083521	07-04-2000	Acemoglu et al.	
	16	US-6080409	06-27-2000	Laus et al.	
	17	US6063905	05-16-2000	Capra et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	18	CA-2139756 Abstract	01-20-1994	Bonnem et al.		
	19	EP-0382381B1	05-26-1993	Schering Corp.		
	20	EP-0326149 B1	08-18-1993	Green Cross Corp.		
	21	EP-0183350 B1	01-15-1992	Immunex Corp.		
	22	EP-0351876 A2	01-24-1990	Ajinomoto Co., Inc.		
	23	EP-0370656 A1	05-30-1990	Schering Corp.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	4	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	70	WALSH, "Biopharmaceutical Benchmarks-2003," Nature Biotechnology 21 (8):865-870 (2003)			
	71	PARDOLL, "Gene-Targeted Immunotherapy of Renal Cancer," Grant No. 1U01CA061551-01 + (Abstract) <a href="http://commons.cit.nih.gov/crisp3/CRISP_LIB">http://commons.cit.nih.gov/crisp3/CRISP_LIB</a> , accessed 9/4/2002			
	72	BENDANDI, "Role of anti-idiotypic vaccines in the modern treatment of human follicular lymphoma," Expert Rev. Anticancer Ther. 1(1):65-72 (2001)			
	73	JAFFEE et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," J. of Clin. Oncology 19(1):145-156 (2001)			
	74	SELMAYR et al., "B-Cell Lymphoma Idiotypes Chimerized by Gene Targeting Can Induce Tumor Immunity," Cancer Gene Therapy 7(3):501-506 (2000)			
	75	BENVENUTI et al., "Anti-Idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection," Gene Therapy 7(7):605-611 (2000)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	5	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	84	BALTIMORE et al., "Expression of the Abelson Murine Leukemia Virus Genome and of Transfected $\kappa$ Immunoglobulin Genes," J. of Cell. Biochem. 12th Annual UCLA Symposia Abstracts, Suppl. 7A, Abstract 0224 (1983)			
	85	BANERJI et al., "Expression of a $\beta$ Globin Gene is Enhanced by Remote SV40 DNA Sequences," Cell 27:299-308 (December 1981) Part 1			
	86	BERNARD et al., "Sequences of Mouse Immunoglobulin Light Chain Genes before and after Somatic Changes," Cell 15: 1133-1144 (1978)			
	87	BIXLER and PILLAI, "Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine Against Haemophilus Influenza B," in Atassi, ed., Immunobiology of Proteins and Peptides VI, Plenum Press, New York, pp.185-190 (1991)			
	88	BONNEM, "Alpha Interferon: The Potential Drug of Adjuvant Therapy: Past Achievements and Future Challenges, Eur. J. Cancer, 27 (Suppl.4):S2-S7 (1991)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	6	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	89	BONNEM, "Granulocyte-macrophage colony stimulating factor - issues in patient management," in Maroun et al., eds., Colony-Stimulating Factors in Clinical Practice, Intl. Congress and Symposium Series No. 184, Royal Society of Medicine Services Ltd., London, pp.17-22 (1992)			
	90	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Biology and Potential Clinical Utility," in Oldham, ed. Principles of Cancer Biotherapy, 2nd ed. Marcel Dekker Inc., New York, Ch. 20, pp.585-598 (1991)			
	91	BONNEM and MORSTYN, "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Current Status and Future Development," Seminars in Oncology 15(5)(Suppl 5):46-51 (1988)			
	92	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor: Unrealized Potential," in Murphy ed. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology, AlphaMed Press, Dayton Ohio pp.37-47 (1991)			
	93	BONNEM et al., "Summary of Preclinical/Clinical Phase I Studies With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)," Investigational New Drugs: The Journal of New Anticancer Agents, Abstract 235, 7(4):407 (1989)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	7	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	94	BOSS and EMTAGE, "Expression of an Immunoglobulin Light Chain Gene in Escherichia Coli," Gene Expression, Alan R. Liss, Inc. New York, pp.513-522 (1983)			
	95	CLARK and CROCE, "An Autonomously Replicating Vector for Mammalian Cells," Plasmids and Transforming Vectors, Fed. Proc. 1983, Abstract 2384			
	96	COLMAN et al., "Interactions of Mouse Immunoglobulin Chains within Xenopus Oocytes," J. Mol. Biol. 160:459-474 (1982)			
	97	CREIGHTON, T.E., Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp.79-86, 1983			
	98	DOLBY et al., "Cloning and partial nucleotide sequence of human immunoglobulin $\mu$ chain cDNA from B cells and mouse-human hybridomas," PNAS USA 77(10):6027-6031 (1980)			
	99	DUMANN et al., "Influence of Thymopentin on Antibody Response and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccination," Nephron 55:136-140 (1990)			
Examiner signature					Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	8	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	100	FALKNER and ZACHAU, "Expression of mouse immunoglobulin genes in monkey cells," Nature 298:286-288 (1982)			
	101	FRIEDMAN et al., "Introduction of the Human HPRT Gene into Mammalian Cells by an Infectious Retroviral Vector," Control of Phospholipid Metabolism, Fed. Proc. 1983, Abstract 1736			
	102	FULIANO et al., "La timopentina come terapia adiuvante nella vaccinazione anti-epatite B in soggetti non-O iporesponsivi," Minerva Medica 81(5):407-413 (1990)			
	103	FUJISAWA et al., "Direct expression of hepatitis B surface antigen gene in E. coli," Nucleic Acids Res. 11(11):3581-3591 (1983)			
	104	GILLIES and TONEGAWA, "Expression of cloned immunoglobulin genes introduced into mouse L cells," Nucleic Acids Res. 11(22):7981-7997 (1983)			
	105	GILLIES et al., "A Tissue-specific Transcription Enhancer Element is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene," Cell 33:717-728 (1983)			
	106	GLENNIE and STEVENSON, "Univalent antibodies kill tumour cells in vitro and in vivo," Nature 295:712-714 (1982)			
	107	GOUGH et al., "Molecular Cloning of Seven Mouse Immunoglobulin K Chain Messenger Ribonucleic Acid," Biochemistry 19:2702-2710 (1980)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	9	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	108	GOUGH, "The rearrangements of immunoglobulin genes," in Tooze et al., eds., Trends in Biochemical Sciences, Reference Edition, Vol. 6, International Union of Biochemistry and Elsevier/North-Holland, 1981, pp.203-205.			
	109	GUARENTE et al., "Improved Methods for Maximizing Expression of a Cloned Gene: a Bacterium That Synthesizes Rabbit $\beta$ -Globin," Cell 20:543-553 (1980)			
	110	HEATH and PLAYFAIR, "Cytokines as immunological adjuvants," Vaccine 10(7):427-434 (1992)			
	111	HESS et al., "The effect of granulocyte-macrophage-colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients," J. of Viral Hepatitis 3:149-153 (1996)			
	112	HITZEMAN et al., "Secretion of Human Interferons by Yeast," Science 219:620-625 (1983)			
	113	HOZUMI et al., "Characterization of a mouse DNA clone containing an immunoglobulin variable region gene," Nucleic Acids Res. 5(6):1779-1799 (1978)			
	114	KEMP and COWMAN, "Direct immunoassay for detecting Eschericia coli colonies that contain polypeptides encoded by cloned DNA segments," PNAS USA 78(7):4520-4524 (1981)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	10	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	115	KNUTH et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," Current Opinion in Immunol. 3:659-664(1991)			
	116	KUROKAWA et al., "Expression of human immunoglobulin E C Chain cDNA in E. coli," Nucleic Acids Res. 11(10:3077-3085 (1983)			
	117	LAU and KAN, "Construction of Recombinant DNA Libraries Using Expression Cosmid Vectors That Can Shuttle Between Bacteria and Mammalian Cells," Plasmids and Transforming Vectors, Fed. Prec. 1983, Abstract 2362, p.2161			
	118	LESLIE et al., "Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines," Immunol. Cell Biol. 68::107-112(1990)			
	119	LEVY, "Cytokine Fusion Proteins with Enhanced Immunogenicity," NIH Grant No. 1R01AI037219-01 (1994) - PC			
	120	LIESCHKE et al., "Effects of Bacterially Synthesized Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy," Annals of Internal Med. 110:357-364 (1989)			
	121	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Part 1", N. Eng. J. of Med. 327(1):28-35 (1992)			
	122	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Part 2", N. Eng. J. of Med. 317(2):99-106 (1992)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	11	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	123	MARTIN et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in the Treatment of Chronic Hepatitis B," Am. Assoc. for the Study of Liver Diseases Abstracts of Papers 16(2, Pt.2):67A, Abstract 89 (1992)			
	124	MASUCCI et al., "Chemotherapy and Immunotherapy of Colorectal Cancer," Med. Oncol. & Tumor Pharmacother. 8 (3): 207-220 (1991)			
	125	MASUCCI et al., "CM-CSF Augments the Cytotoxic Activity of Mononuclear Cells in ADCC Using MAb 17-1A Both $\infty$ -IFN and TNF- $\alpha$ Acts Synergistically," Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7-10, 1989, Abstract 143			
	126	MASUCCI et al., "Granulocyte-monocyte colony-stimulating factor agments the interleukin-2-induced cytotoxic activity of huma lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)," Cancer Immunol. Immunother. 31:231-235 (1990)			
	127	McCUNEune and MARQUIS, "Interleukin 1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor Model," Cancer Res. 50:1212-1215 (1990)			
	128	MERCEREAU-PUIJALON et al., "Expressions of Cloned Eukaryotic Genes in Microorganisma," in Pettersson et al, eds. Expression of Eukaryotic Viral and Cellular Genes, Academic Press, 1981, pp.295-303			
	129	The Merck Manual of Diagnosis and Therapy, eds. Beers M.H. and Berkow R., 17th Ed., 1999, Merck Research Laboratories, Whitehouse Station, N.J., pp. 955-962 Ch. 39			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	12	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	130	MEUER et al., "Low-Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAG in Immunodeficient Non0Responders to Hepatitis B Vaccination," The Lancet, Jan. 7, 1989, pp.15-18			
	131	MEUER et al., "Monocyte Defect in Hemodialysis Patients Supports Nonresponsiveness to Hepatitis B Vaccination and Development of HBsAG Carrier State," in Zukerman, ed., Viral Hepatitis and Liver Disease, Alan R. Liss, Inc., New York, pp.711-713 (1988)			
	132	MEUER et al., "Selective Blockade of the Antigen-Receptor-Mediated Pathway of T Cell Activation in Patients with Impaired Primary Immune Responses," J. Clin. Invest. 80:743-749 (1987)			
	133	Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, New York (1982), p. 433			
	134	MONK et al., "Heavy-Chain Mutants Derived from Y2b Mouse Myeloma: Characterization of Heavy-Chain Messenger Ribonucleic Acid, Proteins, and Secretion in Deletion Mutants and Messenger Ribonucleic Acis in Y2a Mutant Progeny," Biochem. 20:2330-2339 (1981)			
	135	MORRISON, "Transfer and Expression of Immunoglobulin Genes," Ann. Rev. Immunol. 2:239-256 (1984)			
	136	MORSTYN et al., "Pharmacology of colony-stimulating factors," in Abbott, et al., eds., Trends in Pharmacological Sciences, 10:154-159 (1989)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	13	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	137	MOXON, "The scope of immunisation," The Lancet, Feb. 24, 1990, pp.448-451			
	138	MULLIGAN and BERG, "Expression of Bacterial Gene in Mammalian Cells," Science 209:1422-1427 (1980)			
	139	MULLIGAN and BERG, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase," PNAS USA 78(4):2072-7076 (1981)			
	140	MYERS and GUSTAFSON, "Adjuvants for Human Vaccine Usage: A Rational Design," Ch. 32 in Cryz, ed., Vaccines and Immunotherapy, Pergamon Press, Inc., New York, 1991, pp.404-410			
	141	NEUBERGER, "Expression and regulation of immunoglobulin heavy chain gene transfecting into lymphoid cells, EMBO Journal 2(8):1373-1378 (1983)			
	142	NISONOFF and RIVERS, "Recombination of a Mixture of Univalen Antibody Fragments of Different Specificity," Archives of Biochemistry and Biophysics Vol. 93, Academic Press, New York and London, pp.460-462 (1961)			
	143	O'BRIEN et al., "Cloning and sequencing of the cDNA for ovine granulocyte-macrophage colony-stimulating factor (GM-CSF): Immunol. And Cell Biol. 69:51-55 (1991)			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	14	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	144	OCHI et al., "Functional Immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells," PNAS USA 80:6351-6355 (1983)			
	145	OCHI et al., "Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody production," Nature 302:340-342 (1983)			
	146	OI et al., "Immunoglobulin gene expression in transformed lymphoid cells," PNAS USA 80:825-829 (1983)			
	147	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," Molecular and Cell. Biol. 3(2):280-289 (1983)			
	148	PELLICER et al., "Altering Genotype and Phenotype by DNA-Medicated Gene Transfer," Science 209:1414-1421 (1980)			
	149	PICARD and SCHAFFNER, "Correct transcription of a cloned mouse immunoglobulin gene in vivo," PNAS USA 80:417-421 (1983)			
	150	QUIROGA et al., "Recombinant $\gamma$ -Interferon as Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients," Hepatology 12(4):661-663 (1990)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	15	of	18	Attorney Docket Number	30795-702.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	151	RASO and GRIFFIN, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin-bearing Target Cells," Cancer Res. 41:2073-2078 (1981)	
	152	REEVES et al., "Construction and Transfer into Mammalian Cells of a Vector Containing Insect Histone Genes," in Lurquin, et al., eds., Genetic Engineering in Eukaryotes," Plenum Press, New York, pp.73-85 (1983)	
	153	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton PA 1990	
	154	RICE et al., "Expression of Immunoglobulin Genes introduced into Mouse Lymphoid Cell Lines," J. Cell. Biochem. Suppl 7A:133 (Abstract 0341) (1983)	
	155	RICE and BALTIMORE, "Regulated expression of an immunoglobulin K gene introduced into a mouse lymphoid cell line," PNAS USA 79:7862-7865 (1982)	
	156	ROBERTS, et al., "A general method for maximizing the expression of a cloned gene," PNAS USA 76(2):760-764 (1979)	
	157	ROBERTS, "A lac Promoter System for the Overexpression of Prokaryotic and Eukaryotic Genes in E coli," in Rodriguez, et al., eds., Promoters, Structure and Function, Praeger Publishers, New York, 1982, pp.,452-461	
	158	ROBERTS et al., "Synthesis of simian virus 40 t antigen in Excherichia coli," PNAS USA 76(11):5596-5600 (1979)	
Examiner signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	16	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	159	SAMBROOK et al., "Cloning into Bacteriophage M13 Vectors and Transfection of Competent Bacteria," in Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York, 1989, pp.4.33-4.34			
	160	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," Mol. Immunol. 28(3):295-299 (1991) - PC			
	161	SIMS et al., "Somatic Mutation in Genes for the Variable Portion of the Immunoglobulin Heavy Chain," Science 216:309-311 (1982)			
	162	SOUTHERN and BERG, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," J. of Mol. And App. Genetics 1:327-341 (1982)			
	163	STAFFORD and QUEEN, "Cell-type specific expression of a transfected immunoglobulin gene," Nature 306:77-79 (1983)			
Examiner signature		Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	17	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	164	STEWARD et al., "Clinical Studies with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," International J. of Cell Cloning 8:335-346, Suppl. 1 (1990)			
	165	STEWARD et al., "Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions-a phase I dose-toxicity study," Br. J. Cancer 59:142-145 (1989)			
	166	SUBRAMANI, "Expression of the Mouse Dihydrofolate REductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors," Mol. And Cell Biol. 2:854-864 (1981)			
	167	SULLIVAN and MANDELL, "The role of cytokines in infection," Curr. Op. in Infectious Diseases 4:344-349 (1991)			
	168	TAN et al. Biotechn. Appl. Biochem. 1999;30:59-64			
	169	TANIGUCHI et al., "Expression of the human fibroblast interferon gene in Escherichia coli," PNAS USA 77(9):5230-5233 (1980)			
	170	TONEGAWA, "Somatic Generation of Immune Diversity," Nobel lecture, Dec. 8, 1987			
	171	VALLE et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of Xenopus oocytes," Nature 300:71-74 (1982)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	18	of	18	Attorney Docket Number	30795-702.201
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	172	VALLE et al., "Synthesis and secretion of mouse immunoglobulin chains from <i>Xenopus</i> oocytes," <i>Nature</i> 291:338-340 (1981)			
	173	VEELKEN et al., Rapid Expression Cloning of B Cell Lymphoma-Derived Immunoglobulin Genes for Anti-Idiotypic Vaccination and Functional Analyses of Fab-Fragments," <i>Blood</i> 90(10):515A (1997)			
	174	VOSE et al., "Granulocyte-monocyte colony-stimulating factor (GM-CSF): Answers or More Questions?" <i>Annals of Internal Med.</i> 116(3):261-262 (1992)			
	175	WETZEL et al., "Expression in <i>Escherichia coli</i> of a chemically synthesized gene for a "mini-C" analog of human proinsulin," <i>Gene</i> 16:63-71 (1981)			
	176	WIGLER et al., "Transformation of Mammalian Cells with Genes from Prokaryote and Eucaryotes," <i>Cell</i> 16: 777-785 (1979)			
	177	WILLIAMS et al., "Cytoplasmic Inclusion Bodies in <i>Escherichia coli</i> Producing Biosynthetic Human Insulin Proteins," <i>Science</i> 215:687-689 (1982)			
Examiner signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*